Ipamorelin vs Teriparatide
Well Studied vs Extensively Studied
synergistic Mechanism-based · 47% Ipamorelin and Teriparatide work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ipamorelin Teriparatide
Weight 711.85 Da 4,118 Da
Half-life ~2 hours ~1 hour (subcutaneous); ~5 minutes (intravenous)
Chain 5 amino acids 34 amino acids
Type Growth hormone secretagogue Recombinant PTH fragment
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Teriparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic)
03 Increases spine bone density by 5-9%
04 Reduces vertebral fracture risk by 65%
05 Reduces nonvertebral fractures by 35%
06 Works differently than antiresorptive drugs
07 Benefits seen within 3 months
08 Creates 'anabolic window' for bone growth
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Teriparatide
20mcg daily (FDA-approved dose) / Once daily at same time each day
Osteoporosis treatment 20 mcg Once daily
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Teriparatide
Injection site reactions
Nausea
Headache
Leg cramps
Dizziness
Joint pain
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Paget's disease of bone
Prior skeletal radiation therapy
History of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy
Research Evidence
Ipamorelin Teriparatide
Status Well Studied Extensively Studied
References 5 studies 4 studies
Latest October 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.